Enzo Biochem, Inc. (NYSE:ENZ) Sees Large Drop in Short Interest

Enzo Biochem, Inc. (NYSE:ENZ - Get Free Report) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 433,000 shares, a decline of 9.3% from the October 31st total of 477,500 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average trading volume of 86,700 shares, the days-to-cover ratio is presently 5.0 days.

Enzo Biochem Stock Down 0.9 %

Shares of ENZ traded down $0.01 during mid-day trading on Monday, reaching $1.07. 190,489 shares of the stock traded hands, compared to its average volume of 101,008. The firm has a fifty day moving average price of $1.11 and a 200 day moving average price of $1.11. Enzo Biochem has a 1 year low of $0.93 and a 1 year high of $1.50.

Enzo Biochem Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 15th will be issued a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 37.38%. The ex-dividend date is Friday, November 15th.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Enzo Biochem in a report on Sunday. They issued a "hold" rating on the stock.

Institutional Trading of Enzo Biochem

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its holdings in shares of Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company's stock valued at $2,725,000 after buying an additional 64,417 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company's stock worth $31,000 after acquiring an additional 13,735 shares in the last quarter. BBR Partners LLC bought a new stake in shares of Enzo Biochem in the 3rd quarter worth approximately $112,000. Finally, Geode Capital Management LLC boosted its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company's stock valued at $413,000 after purchasing an additional 11,742 shares in the last quarter. Hedge funds and other institutional investors own 36.90% of the company's stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.